- Home
- HCM vs SRRK Comparison
HCM vs SRRK Comparison
Compare HCM & SRRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HCM | SRRK |
|---|---|---|
| Founded | 2000 | 2012 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 3.0B |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | HCM | SRRK |
|---|---|---|
| Price | $14.13 | $45.19 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 1 | 9 |
| Target Price | $13.75 | ★ $47.00 |
| AVG Volume (30 Days) | 29.0K | ★ 2.1M |
| Earning Date | 08-07-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.53 | N/A |
| Revenue | ★ $602,197,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $15.54 | $20,271.77 |
| P/E Ratio | $5.26 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $11.51 | $22.71 |
| 52 Week High | $19.50 | $46.98 |
Technical Indicators
Market Signals| Indicator | HCM | SRRK |
|---|---|---|
| Relative Strength Index (RSI) | 37.46 | 70.72 |
| Support Level | $14.11 | $39.51 |
| Resistance Level | $14.63 | $43.94 |
| Average True Range (ATR) | 0.27 | 2.52 |
| MACD | -0.01 | 0.62 |
| Stochastic Oscillator | 21.69 | 98.35 |
Price Performance
Historical ComparisonAbout HCM HUTCHMED (China) Limited
HUTCHMED (China) Ltd is an biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.
About SRRK Scholar Rock Holding Corporation
Scholar Rock Holding Corp is a late-stage biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for treating serious diseases in which signaling by protein growth factors plays a fundamental role. Its pipeline includes Neuromuscular and Obesity, Immuno-oncology, Fibrotic Disease, and Hematology. The group operates and manages its business as a single segment to assess performance and make operating decisions.